New plague vaccine enters human testing
NCT ID NCT07207408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine called rF1V-1018 to prevent pneumonic plague, a severe lung infection spread by aerosol. Researchers will give the vaccine to 148 healthy adults aged 18 to 55 to check if it triggers a strong immune response and is safe. The goal is to find the best dose and schedule for future larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rF1V-1018 vaccine
What this could lead to
If successful, this could lead to a vaccine that protects people from pneumonic plague, a rare but deadly lung infection caused by Yersinia pestis.
What could go wrong
This is an early Phase 2 trial with only 148 participants, so results may not apply to everyone. The vaccine may not produce strong enough immunity or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF PNEUMONIC PLAGUE RESULTING FROM AEROSOL EXPOSURE TO YERSENIA PESTIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
103
ACTIVE_NOT_RECRUITINGMiami, Florida, 33172, United States
-
AMR- El Dorado
ACTIVE_NOT_RECRUITINGEl Dorado, Kansas, 67042, United States
-
AMR- Las Vegas
ACTIVE_NOT_RECRUITINGLas Vegas, Nevada, 889119, United States
-
CTI Clinical Research Center
RECRUITINGCincinnati, Ohio, 45212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••